Bax Knockout 293T Cell Line

Description

Bax Knockout 293T Cell Line is engineered from human embryonic kidney 293T cells through CRISPR/Cas9-mediated disruption of the BCL2-Associated X Protein (Bax) gene, a key pro-apoptotic regulator of mitochondrial outer membrane permeabilization and intrinsic apoptosis. This knockout model exhibits profound resistance to apoptotic stimuli while maintaining 293T cells’ characteristic adherent growth with epithelial morphology and high transfection efficiency. The cell line provides a critical tool for studying programmed cell death mechanisms, cancer therapy resistance, and mitochondrial dysfunction, particularly in research involving chemotherapeutic agents and DNA damage responses. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through multiplex verification including genomic PCR, Sanger sequencing, and functional apoptosis assays demonstrating impaired cytochrome c release. The cell line has undergone rigorous quality control and is certified free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The Bax Knockout 293T Cell Line is a valuable model for studying intrinsic apoptosis and mitochondrial-mediated cell death pathways. This engineered system enables investigation of Bax’s essential role in cytochrome c release and caspase activation. Researchers utilize this knockout line to examine apoptosis resistance mechanisms and evaluate therapeutic compounds targeting Bcl-2 family proteins. The cell line provides a controlled platform for analyzing cell survival regulation and developing novel cancer treatment strategies.